PART I Overview We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies to patients. We have pioneered a therapeutic approach that we generally refer to as cellular programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; after the engineering step that incorporates multiple functional elements into the iPSCs, we generate a clonal m...
Q2 FY2026 — expected 2026-08-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073699 | EDGAR | 109K words |
| 2025-03-05 | 2024-12-31 | 0000950170-25-033510 | EDGAR | — |
| 2024-02-26 | 2023-12-31 | 0000950170-24-020158 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005067 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002293 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001564590-21-008086 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001564590-20-008141 | EDGAR | — |
| 2019-03-05 | 2018-12-31 | 0001564590-19-006258 | EDGAR | — |
| 2018-03-05 | 2017-12-31 | 0001564590-18-004394 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001564590-17-004614 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-279096 | EDGAR | 68K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107309 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070285 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125317 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096187 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056869 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061080 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039803 | EDGAR | — |
| 2023-05-03 | 2023-03-31 | 0000950170-23-017175 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021840 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0000950170-22-014236 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007389 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001193125-26-073689 | EDGAR | 4K words |
| 2025-11-13 | 0001193125-25-279091 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250674 | EDGAR | — |
| 2025-10-14 | 0001193125-25-238989 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178947 | EDGAR | — |
| 2025-05-30 | 0001193125-25-132301 | EDGAR | — |
| 2025-05-13 | 0000950170-25-070280 | EDGAR | — |
| 2025-03-05 | 0000950170-25-033507 | EDGAR | — |
| 2025-01-06 | 0001193125-25-002153 | EDGAR | — |
| 2024-11-29 | 0001193125-24-268003 | EDGAR | — |
218 total filings indexed. 186 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001434316 |
| Ticker | FATE |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.fatetherapeutics.com |
| Listed | 2013-10-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report